Biomarker establishment for novel cure therapy for dilated cardiomypathy

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09096
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Cardiovascular medicine
• Research Institution: Tokyo Dental College (2016-2017); Kitasato University (2015)
• Principal Investigator: Baba Akiyasu 東京歯科大学, 歯学部, 講師 (60296572)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 拡張型心筋症 / 重症心不全 / 免疫吸着療法 / アフェレシス / 心筋自己抗体 / バイオマーカー

Outline of Final Research Achievements

Immunoadsorption therapy is expected as a novel cure therapy for patients with dilated cardiomyopathy, so present study was performed in order to establish blood tests to efficiently treat those patients by this therapy.　Autoantibodies against heart were measured in multiple ways using the blood of patients treated with “Advanced Medical Care B（MHLW）”. It was found that optimal treatment can be performed by measuring the autoantibody which could directly suppress heart function (Cardio-depressant autoantibody) before and after the immunoadsorption therapy against heart failure. Furthermore, it was also clarified that simple ELISA method can estimate the cardio-depressant autoantibody by simultaneously combining multiple autoantigens.

Free Research Field

循環器内科